Oxford University and Anglo-Swedish Pharmaceutical Company Astrazeneca, who had previously developed a vaccine from coronavirus, began to create a version of the drug intended to combat “Omicron”, transmits TASS.
“together with the Oxford University we have taken preliminary steps towards the production of a variant vaccine against” Oomikron “in case it will be needed,” the FINANCIAL TIMES newspaper is given.
According to the head of the research team in Oxford Sandy Douglas, adenovirus-based vaccines (manufactured, for example, Oxford University and Astrazeneca), in principle, can be used to quickly respond to any new strain than previously expected. He noted that such vaccines have really important advantages, especially where the greatest problems are associated with supply and logistics.
According to information, if necessary, researchers will be able to develop a vaccine modification within 100 days.